Biontech CEO - Search News

BioNTech to buy Biotheus, gaining control of cancer bispecific

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit Therapeutics’ ivonescimab.

Business Insider · 19h

BioNTech to acquire Biotheus for upfront consideration of $800M

BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology

MarketWatch · 1d

BioNTech to Acquire Biotheus in $950 Million Deal

The tie-up will also expand BioNTech's footprint in China, giving it a local research and development hub for clinical trials, as well as a new biologics manufacturing facility and more than 300 Biotheus employees,

Reuters on MSN · 1d

BioNTech buys China's Biotheus to support oncology strategy

German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.

Business Insider · 1d

BioNTech to Acquire Biotheus to Boost Oncology Strategy

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational

9don MSN

BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

Yahoo Finance1mon

'Where we are today in biology AI is similar to GPT in 2020': An interview with the CEO of Africa's biggest AI startup

Fifteen months on from completion of the BioNTech acquisition, co-founder and CEO Karim Beguir told TechCrunch in an interview that InstaDeep has made significant progress on that front ...

Business Insider10d

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We remain focused on advancing our late-stage oncology product candidates towards potential registration. We believe our pipeline and ...

FiercePharma7d

Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

AOL16d

Pfizer CEO: The activist investors are 'too late'

Starboard CEO Jeff Smith told Bourla that the COVID ... Biohaven deal and the COVID vaccine revenue-sharing deal with BioNTech (BNTX) are key to near-term growth. Those deals have been ...

15don MSN

Pfizer CEO Defends Turnaround Strategy as Activist Pressures Management

(Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results